AMGN

Amgen Inc

Trading Strategies

Here's the Best Time to Buy AAPL and TSLA Stock

by

For the 56th time since 1896, the Dow Jones has spiced things up – Exxon Mobil, Pfizer, and Raytheon are out, and "new economy," biotech, and tech stocks Salesforce.com, Amgen, and Honeywell International are in.

But for sharp traders, the real story – and the real opportunity – is over on the high-flying NASDAQ Composite.

Sure, the endless string of new record highs is nice, but I'm talking about the stock splits approved by the boards of Apple and Tesla. AAPL and TSLA shares split 4-for-1 and 5-for-1, respectively.

That ignited monster rallies in both stocks and, in short order, long-term bulls will get a beautiful entry point.

The thing is, it's not right now.

I'm going to show you the signal to watch for to know exactly when to strike for profit… Full Story

I'm going to show you the signal to watch for to know exactly when to strike for profit...

Dow Jones

Why the Dow Jones Swapped Out Three Stocks Today

by

The Dow Jones Industrial Average executed a minor overhaul today.

As of the opening bell, three stocks were removed from the index and three new stocks added in their place.

Dow Jones said it took the action because of the impact of the Apple stock split – it didn't want the tech sector to have less influence.

But how will this affect the DJIA and its component stocks going forward?.

Here's everything you need to know...

Dow Jones

Dow Jones Now Flat After Stocks Leave the Index

by

The Dow Jones now is flat after Salesforce.com (NYSE: CRM), Amgen (NASDAQ: AMGN), and Honeywell (NYSE: HON) replace Exxon Mobil (NYSE: XOM), Pfizer (NYSE: PFE) and Raytheon (NYSE: RTN) on the index.

This week, the S&P 500 and NASDAQ reached milestones since hitting intraday lows in March.

Gains are 57% and 72%, respectively.

Read more...

Biotechnology

This "Orphan Drug" Biotech Could Double in Less Than Three Years

by

The three biggest Big Pharma "blockbuster" medicines of all time target high cholesterol (Lipitor), inflammatory diseases (Humira), and digestive afflictions (Nexium) and have pulled in a combined $350 billion – and counting.

But what about people suffering from rare diseases like cystic fibrosis, pancreatic cancer, and so on?

Here in America, Washington understands the need for these "orphan drugs" targeting rare diseases, which is why the "Orphan Drug Act of 1983" offers a seven-year window of tax reductions and the exclusive right to market a drug for a particular rare disease.

To date, more than 600 orphan drugs have been approved by the FDA.

And the global market for orphan drugs targeting rare diseases is growing at double the rate of the non-orphan market.

But more needs to be done. And that "more" will create a massive investment portal – provided you pick the best-positioned companies.

That's why today, our Michael Robinson going to show you a revved-up leader in the specialty-drugs market whose shares could double in under three years...

Biotechnology

How to Cash In on the Biggest Medical Breakthrough of the Decade

by

Imagine if all it took to treat a case of cancer was taking out the trash.

Now, I want you to imagine that your body could do it all for you.

Hold that thought. Because a tech platform with that very task in mind is set to hit the market sooner than you think and will target a field set to be worth more than $160 billion.

Here's the thing. Several life sciences firms are hard at work perfecting a new class of drugs known as "degraders."

Let me explain. The root of many diseases lies in misguided proteins that bind together. So, the idea here is to come up with a new class of drugs that activate the body's own molecular trash disposal systems.

This is one of the most exciting breakthroughs I've come across in many years. I believe it puts us close to the day when one pill can cure dozens, if not all, diseases.

And in a moment, I'm going to reveal a way investors can target the entire class of protein degraders with one savvy move...